Nautilus Biotechnology NAUT
NASDAQ NAUT
$0.95 +0.05 (+5.79%)
At close: Aug 21, 2026 · 4:00 PM EDT

Nautilus Biotechnology (NAUT) Amortizatization of Intangibles (2020 - 2026)

Nautilus Biotechnology (NAUT) posted Amortizatization of Intangibles of -$12000.0 for Q2 2026, down 117.65% sequentially from $68000.0 in Q1 2026, and down 102.73% YoY from $439000.0 in Q2 2025.

Nautilus Biotechnology (NAUT) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends

Nautilus Biotechnology has reported Amortizatization of Intangibles for 7 years, with the latest figure at -$12000.0 in Q2 2026.

  • Quarterly Amortizatization of Intangibles fell 102.73% year-over-year to -$12000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $496000.0 (down 78.72% YoY) and the FY2025 annual result came in at $1.4 million, down 49.36% from the prior year.
  • Amortizatization of Intangibles slipped to -$12000.0 in Q2 2026 per NAUT's latest filing, from $68000.0 in the prior quarter.
  • Over five years, Amortizatization of Intangibles peaked at $751000.0 in Q1 2024 and troughed at -$26000.0 in Q1 2022.
  • A 5-year average of $434944.4 and a median of $545500.0 in 2022 frame the typical range for Amortizatization of Intangibles.
  • The sharpest annual moves came in 2022 and 2026: Amortizatization of Intangibles soared 7757.14% in 2022, then plunged 102.73% in 2026.
  • Over 5 years, Amortizatization of Intangibles stood at $550000.0 in 2022, then rose by 12.55% to $619000.0 in 2023, then grew by 1.45% to $628000.0 in 2024, then plunged by 78.66% to $134000.0 in 2025, then slumped by 108.96% to -$12000.0 in 2026.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$12000.0, $68000.0, and $134000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 678,000.00
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Nautilus Biotechnology 120.16 Mn 120.16 Mn 175,000.00 1.01 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -12,000.00
Jun 30, 2026 -12,000.00
Mar 31, 2026 68,000.00
Mar 31, 2026 68,000.00
Dec 31, 2025 134,000.00
Dec 31, 2025 134,000.00
Sep 30, 2025 306,000.00
Sep 30, 2025 306,000.00
Jun 30, 2025 439,000.00
Jun 30, 2025 439,000.00
Mar 31, 2025 541,000.00
Mar 31, 2025 541,000.00
Dec 31, 2024 628,000.00
Dec 31, 2024 628,000.00
Sep 30, 2024 723,000.00
Sep 30, 2024 723,000.00
Jun 30, 2024 702,000.00
Jun 30, 2024 702,000.00
Mar 31, 2024 751,000.00
Mar 31, 2024 751,000.00